Geoffrey Gibney

Hematology | Oncology
3800 Reservoir Rd Nw
Washington, DC 20007

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications

Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma.

Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: July 16, 2026

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026

Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.

Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: June 30, 2026

Developing a Culturally Tailored Narrative Video for Skin Cancer Prevention Among Spanish-Speaking Hispanic Outdoor Workers: Co-Design Study.

Developing a Culturally Tailored Narrative Video for Skin Cancer Prevention Among Spanish-Speaking Hispanic Outdoor Workers: Co-Design Study.

Journal: Journal of participatory medicine
Published: December 25, 2025

Cellular Therapy for Advanced Melanoma.

Cellular Therapy for Advanced Melanoma.

Journal: The Surgical clinics of North America
Published: May 24, 2025

Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.

Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma.

Journal: Pigment cell & melanoma research
Published: April 27, 2025

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.

Journal: Cancer medicine
Published: April 11, 2025

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Journal: Cancer
Published: April 08, 2025

Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.

Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2024

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Journal: The British journal of dermatology
Published: July 30, 2024

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.

Journal: Gynecologic oncology
Published: March 12, 2024

Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Journal: Cancer research communications
Published: March 04, 2024
Showing 1-12 of 89

Last Updated: 09/26/2026